Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Korea's Genexine Out-licenses Three Molecules to Tasly in $100 Million Deal

publication date: Oct 19, 2015
Genexine, a South Korean novel drug developer, out-licensed China rights to three clinical or near-clinical stage biologic drug candidates to Tasly Pharma of Tianjin in a deal worth up to $100 million. In addition, Tasly paid an undisclosed sum to acquire global rights for two Genexine preclinical molecules. For the clinical-stage assets, Genexine will receive $20 million upfront and up to $80 million in development and commercial milestones. Tasly will also pay royalties on sales. A Tasly subsidiary, Tasgen, will be responsible for development of the Genexine products. More details....

Stock Symbols: (KOSDAQ, 095700) (SHA: 600535)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital